ストックスクリーナーアプリを入手
16.77
4.53%
-0.795
アフターアワーズ：
16.80
0.03
+0.18%
前日終値:
$17.57
開ける：
$17.4
24時間の取引高:
240.56K
Relative Volume:
1.10
時価総額：
$760.91M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-6.89%
1か月 パフォーマンス:
+30.10%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$15.58
$17.78
1週間の範囲:
$15.58
$18.33
52週間の値動き範囲:
$12.24
$21.55
Maplight Therapeutics Inc Stock (MPLT) Company Profile
MPLT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
16.77 | 796.98M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-21 | 開始されました | Jefferies | Buy |
| 2025-11-21 | 開始されました | Leerink Partners | Outperform |
| 2025-11-21 | 開始されました | Morgan Stanley | Overweight |
| 2025-11-21 | 開始されました | Stifel | Buy |
Maplight Therapeutics Inc (MPLT) 最新ニュース
MapLight’s phase 2 Alzheimer’s psychosis trial marks a key milestone for MPLT investors - MSN
What is the current Price Target and Forecast for MapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight’s Phase 2 Alzheimer’s Psychosis Trial Marks a Key Milestone for MPLT Investors - TipRanks
MapLight Therapeutics Earnings Notes - Trefis
MapLight Therapeutics advances CNS drug pipeline - MSN
MapLight’s ML-004 Autism Extension Study: What Ongoing Safety Data Mean for Investors - TipRanks
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to S&P TMI Index - marketscreener.com
Aktis Oncology files for US IPO as biotech listings rebound - whbl.com
MapLight2025 Funding Rounds & List of Investors - Tracxn
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to Russell 2000 Growth Index - marketscreener.com
SandboxAQ and MapLight join forces on CNS - The Pharma Letter
6 Biotechs That Could Be Big Pharma’s Next M&A Target - BioSpace
SandboxAQ and MapLight Therapeutics Partner on Novel CNS Therapies - HPCwire
SandboxAQ and MapLight form $200 million CNS drug discovery alliance By Investing.com - Investing.com Nigeria
SandboxAQ and MapLight form $200 million CNS drug discovery alliance - Investing.com
MapLight links up with SandboxAQ to pursue AI-discovered CNS treatments - Axios
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies - The Manila Times
Sandboxaq And Maplight Therapeutics Announce Collaboration To Discover And Develop Novel CNS Therapies - TradingView — Track All Markets
MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes - MSN
Potential Bristol Myers rival MapLight seeks $250M in U.S. IPO - MSN
MapLight Therapeutics completes IPO and raises $296.5M - MSN
Analysts Offer Insights on Healthcare Companies: MapLight Therapeutics, Inc. (MPLT) and Halozyme (HALO) - The Globe and Mail
Maplight Therapeutics (MPLT) Stock Trends and Sentiment 2025 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Adversity is less terrifying than hope: MapLight Therapeutics Inc (MPLT) - setenews.com
MapLight Therapeutics Advances CNS Drug Pipeline - TipRanks
Florida key to BMS slip in ADP? Acadia sails ahead - BioWorld MedTech
Maplight Therapeutics (MPLT) Earnings Date and Reports 2026 - MarketBeat
Maplight Therapeutics reports third quarter financial results - marketscreener.com
MapLight Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - marketscreener.com
MapLight Therapeutics Completes IPO and Raises $296.5M - TipRanks
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress - The Manila Times
MapLight Therapeutics, Inc. SEC 10-Q Report - TradingView
MPLT: Clinical pipeline advances and robust IPO funding position operations through 2027 - TradingView — Track All Markets
Positive Outlook on MapLight Therapeutics Amid ADEPT-2 Study Continuation and Upcoming Catalysts - TipRanks
MapLight stock rises as Jefferies reiterates Buy rating on schizophrenia drug By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
MapLight stock rises as Jefferies reiterates Buy rating on schizophrenia drug - Investing.com Canada
Bristol Myers (BMY) Advances in Alzheimer's Study Facing Trial C - GuruFocus
Marvell Posts Strong Q3 Earnings, Joins American Eagle, Microchip Technology, Box And Other Big Stocks Moving Higher On Wednesday - Benzinga
SETIA VISHWAS Insider Trades - Nasdaq
MapLight Therapeutics (MPLT) Stock Analysis Report | Financials & Insights - Benzinga
MPLT Interactive Stock Chart | MapLight Therapeutics, Inc. Stock - Yahoo! Finance Canada
MapLight Therapeutics, Inc. (MPLT) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
MapLight Therapeutics Closes Successful IPO and Private Placement - MSN
FOFF ERIN PENNOCK Insider Trades - Nasdaq
KROEGER CHRISTOPHER A Insider Trades - Nasdaq
MapLight Therapeutics stock rating reiterated at Overweight by Morgan Stanley - Investing.com Canada
MapLight Therapeutics initiated with a Buy at Stifel - MSN
Maplight Therapeutics Inc (MPLT) 財務データ
Maplight Therapeutics Inc (MPLT) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.57%
大文字化:
|
ボリューム (24 時間):